Back to Search
Start Over
The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma
- Source :
- Journal of Clinical Medicine, Volume 10, Issue 12, Journal of Clinical Medicine, Vol 10, Iss 2732, p 2732 (2021)
- Publication Year :
- 2021
- Publisher :
- Multidisciplinary Digital Publishing Institute, 2021.
-
Abstract
- Incidence and mortality of intrahepatic cholangiocarcinoma (iCCA) have been increasing continuously. Recent studies suggest that the combination of palliative chemotherapy (pCTX) and transarterial chemoembolization (TACE) improves overall survival (OS). This study aimed to evaluate the outcome of patients treated with TACE and pCTX in unresectable iCCA at our tertiary care center. A group of 14 patients was treated with both pCTX and TACE. The non-randomized control group of 59 patients received pCTX alone. Patients received a median of two pCTX lines in both groups. Those treated with TACE underwent a median number of 3.5 sessions. Median OS from the time of unresectability was 26.2 months in the pCTX + TACE group versus 13.1 months in the pCTX group (p = 0.008). Controlling for albumin, bilirubin, ECOG (Eastern Cooperative Oncology Group) performance status, and UICC (Union for International Cancer Control) stage, the addition of TACE still conferred an OS benefit of 12.95 months (p = 0.014). A propensity score matching analysis yielded an OS benefit of 14 months from the time of unresectability for the pCTX + TACE group (p = 0.020). The addition of TACE to pCTX may provide an OS benefit for patients with unresectable iCCA. Thus, patients with liver-dominant iCCA undergoing standard-of-care pCTX should be considered for additional treatment with TACE.
- Subjects :
- medicine.medical_specialty
combined modality therapy
medicine.medical_treatment
chemotherapy
Gastroenterology
survival
Article
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Combined Modality Therapy
Stage (cooking)
chemoembolization
Intrahepatic Cholangiocarcinoma
Chemotherapy
Performance status
business.industry
Incidence (epidemiology)
General Medicine
Palliative chemotherapy
030220 oncology & carcinogenesis
Propensity score matching
Medicine
030211 gastroenterology & hepatology
business
cholangiocarcinoma
Subjects
Details
- Language :
- English
- ISSN :
- 20770383
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Medicine
- Accession number :
- edsair.doi.dedup.....93ea342eed243e6fffb4697ea6f95bd9
- Full Text :
- https://doi.org/10.3390/jcm10122732